Advanced Gout, Asymptomatic Hyperuricemia, Gout Flare, Intercritical Gout
Conditions
Keywords
PBMC monocyte Treg
Brief summary
The purpose of this study is to evaluate whether immune cells and their subtypes in peripheral blood affects the asymptomatic hyperuricemia, gout flare, intercritical gout and advanced gout.
Detailed description
A number of studies have reported that innate immunity cells (such as blood monocytes and neutrophils) play a crucial role in the initiation and amplification of gout flare resulted from MSU deposition in the joint or tissue, leading to release NLRP3 inflammasome-mediated production of bioactive IL-1β. Further investigation demonstrated the role of blood neutrophils might contribute to the resolution of gout flare by forming aggregated neutrophil extracellular traps. Recently, a few in vitro experiments have indicated that adaptive immunity may be involved in mechanisms of gout. However, a global understanding of blood immune responses underlying gout is still unclear. Thus, we want to investigate the relationship between immune cells and their subtypes in peripheral blood and the gout.
Interventions
None listed
Sponsors
Ai Peng
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* gout flare:diagnosis with gout flare at this hospital according to the criteria approved by the ACR Board of Directors and the EULAR Executive Committee in 2015 * intercritical gout: remission of gout patients were classified into intercritical gout group without tophi, chronic gouty arthritis, or imaging erosion(All of these gout remission patients underwent dual-energy CT test within one month, and were detected to have MSU crystal deposition in local joints) * advanced gout: gout remission patients were classified into advanced gout group characterized by tophi, chronic gouty arthritis, or imaging erosion(All of these gout remission patients underwent dual-energy CT test within one month, and were detected to have MSU crystal deposition in local joints) * asymptomatic hyperuricemia: hyperuricemia in men was defined as SUA ≥ 420 mmol/L without any complications
Exclusion criteria
* primary osteoarticular diseases * unwilling participation in the study * corticosteroids or indomethacin use in the past 3 months; * septic arthritis or another joint disease (such as rheumatoid arthritis); * impaired renal function (creatinine clearance \<30 mL/min) and other conditions which may increase the level of blood uric acid
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| remission of gout | 6 month | Patients fulfilling all the domains of the 2016 preliminary remission criteria for gout were defined as gout remission group |
Countries
China
Outcome results
None listed